SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) r...

Por Nahleh, Z. A., Barlow, W. E., Hayes, D. F., Schott, A. F., Gralow, J. R., Sikov, W. M., Perez, E. A., Chennuru, S., Mirshahidi, H. R., Corso, S. W., Lew, D. L., Pusztai, L., Livingston, R. B., Hortobagyi, G. N.
Publicado no Breast Cancer Res Treat (2016)

Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer

Por Brewer, Noel T., DeFrank, Jessica T., Chiu, Wing K., Ibrahim, Joseph G., Walko, Christine M., Rubin, Peter, Olajide, Oludamilola A., Moore, Susan G., Raab, Rachael E., Carrizosa, Daniel R., Corso, Steven W., Schwartz, Garry, Peppercorn, Jeffrey M., McLeod, Howard L., Carey, Lisa A., Irvin, William J.
Publicado em 2014

Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

Por Irvin, William J., Walko, Christine M., Weck, Karen E., Ibrahim, Joseph G., Chiu, Wing K., Dees, E. Claire, Moore, Susan G., Olajide, Oludamilola A., Graham, Mark L., Canale, Sean T., Raab, Rachel E., Corso, Steven W., Peppercorn, Jeffrey M., Anderson, Steven M., Friedman, Kenneth J., Ogburn, Evan T., Desta, Zeruesenay, Flockhart, David A., McLeod, Howard L., Evans, James P., Carey, Lisa A.
Publicado em 2011